ALVO, NGM

Alvotech (ALVO)

Price (as of October 24)

6.06USD

Correlations

The correlation describes the statistical relationship between the value of two assets over time. Use this relationship to bet against an asset without shorting it or diversify your portfolio more effectively. Learn how you can use correlations to your advantage.

Lowest within Industry

Symbol Correlation

HCM

HUTCHMED (China) Limited

-0.35

CTLT

Catalent, Inc.

-0.24

TAK

Takeda Pharmaceutical Company Limited

-0.23

TEVA

Teva Pharmaceutical Industries Limited

-0.22

TLRY

Tilray Brands, Inc.

-0.21

TARO

Taro Pharmaceutical Industries Ltd.

-0.2

NEPT

Neptune Wellness Solutions Inc.

-0.19

GRVI

Upexi, Inc.

-0.19

CRDL

Cardiol Therapeutics Inc.

-0.18

SCTL

Societal CDMO, Inc.

-0.18
Show more

Highest within Industry

Symbol Correlation

IMCC

IM Cannabis Corp.

0.3

QLI

Qilian International Holding Group Limited

0.3

EMBC

Embecta Corp.

0.26

OPTN

OptiNose, Inc.

0.24

EVO

Evotec SE

0.24

PLXP

PLx Pharma Inc.

0.22

AVDL

Avadel Pharmaceuticals plc

0.21

CPHI

China Pharma Holdings, Inc.

0.2

PRFX

PainReform Ltd.

0.2

EVOK

Evoke Pharma, Inc.

0.19
Show more

Profile

Sector:
Healthcare
Industry:
Drug Manufacturers

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.